Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation.
There is increasing evidence that intermittent hypoxia plays a role in the development of cardiovascular risk in obstructive sleep apnoea syndrome (OSAS) through the activation of inflammatory pathways. The development of translational models of intermittent hypoxia has allowed investigation of its role in the activation of inflammatory mechanisms and promotion of cardiovascular disease in OSAS. There are noticeable differences in the response to intermittent hypoxia between body tissues but the hypoxia-sensitive transcription factors hypoxia-inducible factor-1 and nuclear factor-kappaB appear to play a key role in mediating the inflammatory and cardiovascular consequences of OSAS. Expanding our understanding of these pathways, the cross-talk between them and the activation of inflammatory mechanisms by intermittent hypoxia in OSAS will provide new avenues of therapeutic opportunity for the disease.
Garvey
J F
JF
Respiratory Sleep Disorders Unit, St. Vincent's University Hospital, Dublin, Ireland.
Taylor
C T
CT
McNicholas
W T
WT
D000818:Animals; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D016207:Cytokines / Q000502:physiology; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology; D007249:Inflammation / Q000503:physiopathology; D020181:Sleep Apnea, Obstructive / Q000503:physiopathology*; D014157:Transcription Factors / Q000502:physiology
D016207:Cytokines; D014157:Transcription Factors